BS_H8A9PSYA
pilocytic astrocytoma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- pilocytic astrocytoma
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- pilocytic astrocytoma
- overall_survival_months
- 16.78712220762155
- age_years
- 3.811
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- BILE_ACID_METABOLISM+0.408
- ANDROGEN_RESPONSE+0.378
- CHOLESTEROL_HOMEOSTASIS+0.368
- INTERFERON_ALPHA_RESPONSE+0.364
- UV_RESPONSE_DN+0.343
- APICAL_SURFACE+0.331
- PROTEIN_SECRETION+0.285
- MYOGENESIS+0.284
- KRAS_SIGNALING_UP+0.279
- INTERFERON_GAMMA_RESPONSE+0.268
Top 10 suppressed
- E2F_TARGETS-0.563
- MYC_TARGETS_V2-0.551
- MYC_TARGETS_V1-0.535
- G2M_CHECKPOINT-0.479
- DNA_REPAIR-0.447
- OXIDATIVE_PHOSPHORYLATION-0.338
- UNFOLDED_PROTEIN_RESPONSE-0.305
- MITOTIC_SPINDLE-0.242
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.221
- UV_RESPONSE_UP-0.207
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | BS_CTR5X93B | pilocytic astrocytoma | — | 0.875 |
| 2 | BS_GYA4V1RD | pilocytic astrocytoma | — | 0.874 |
| 3 | BS_FXJY0MNH | Diffuse intrinsic pontine glioma | — | 0.869 |
| 4 | BS_GCA4GET3 | low-grade glioma | — | 0.861 |
| 5 | BS_2ADZNNV4 | pilocytic astrocytoma | — | 0.856 |
| 6 | TCGA-CR-7391-01A-11R-2016-07 | — | — | 0.855 |
| 7 | 27a08af2-4626-4bf9-bdf6-a6ba644a53a2 | — | — | 0.850 |
| 8 | TCGA-75-6203-01A-11R-1755-07 | — | cohortA1 | 0.850 |
| 9 | BS_470DYRJQ | pilocytic astrocytoma | — | 0.848 |
| 10 | TCGA-55-7284-01B-11R-2241-07 | — | cohortA1 | 0.840 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 29 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| BILE_ACID_METABOLISM | 0.408 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.378 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.368 | Remibrutinib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.364 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.343 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.331 | Temsirolimus | — uncovered |
| PROTEIN_SECRETION | 0.285 | Remibrutinib | — uncovered |
| MYOGENESIS | 0.284 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.279 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.268 | Idelalisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.259 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.248 | Cobimetinib | — uncovered |
| KRAS_SIGNALING_DN | 0.232 | Remibrutinib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.221 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.209 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.198 | Idelalisib | — uncovered |
| COMPLEMENT | 0.193 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.193 | Temsirolimus | — uncovered |
| COAGULATION | 0.191 | Binimetinib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.183 | Inavolisib | — uncovered |